Compounded semaglutide vs Wegovy®: the key differences

If you have researched semaglutide for weight management, you have probably come across two versions of the same active ingredient: the FDA-approved brand Wegovy® and "compounded semaglutide." They are not interchangeable in the ways that matter most, and the differences are worth understanding before you talk to a clinician. This explainer lays out what Wegovy® is, what changes with a compounded formulation, how their regulatory status compares, and how a clinician actually chooses between options.

This is patient education, not medical advice. Only an independent licensed clinician can decide whether any treatment, brand or compounded, is appropriate for you.

What Wegovy® is as an FDA-approved product

Wegovy® (semaglutide) is FDA-approved for chronic weight management in eligible adults, alongside a reduced-calorie diet and increased physical activity. It is a manufactured, branded product with FDA-reviewed labeling, which means the FDA has evaluated it for safety, efficacy, and quality and approved specific uses, dosing, and warnings.

Semaglutide itself is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works on the GLP-1 hormone pathway involved in appetite signaling, fullness, and blood sugar regulation. You may also know semaglutide under other FDA-approved brand names used for type 2 diabetes, such as Ozempic®; Wegovy® is the brand FDA-approved specifically for chronic weight management.

The key thing to hold onto about Wegovy® is the regulatory assurance behind it: as an FDA-approved product, it comes with standardized manufacturing, an FDA-reviewed label, and a defined set of approved indications and warnings. That is the baseline against which a compounded formulation should be understood.

What differs with a compounded formulation

Compounding is when a licensed pharmacy prepares a medication for an individual patient rather than dispensing a mass-manufactured product. Compounded formulations are prepared by a licensed pharmacy for an individual patient, which is a long-established part of U.S. pharmacy practice. Compounded semaglutide contains the same active molecule, semaglutide, but it is prepared rather than manufactured under a brand's approved process.

The most important difference is regulatory, not chemical. Compounded semaglutide is not FDA-approved, and compounded medications generally have not been reviewed by the FDA for safety, efficacy, or quality. That does not by itself mean a compounded medication cannot be appropriately prescribed, but it does mean the assurance of quality rests on the compounding pharmacy and the prescribing clinician rather than on FDA review of that specific product.

Practical differences can also follow from this. Because a compounded preparation is made for an individual rather than produced as a single standardized branded product, aspects such as formulation details and presentation are handled by the compounding pharmacy under its own standards. This is one reason the choice of pharmacy and prescriber matters so much with any compounded medication.

Regulatory status compared

Placing the two side by side makes the contrast clear:

• Wegovy®: FDA-approved for chronic weight management, with FDA-reviewed labeling covering approved uses, dosing, and warnings.
• Compounded semaglutide: not FDA-approved; not reviewed by the FDA for safety, efficacy, or quality; prepared by a licensed pharmacy for an individual patient.

Why does compounded semaglutide exist at all? Compounding has historically played a role during FDA-declared shortages, when compounding pharmacies may, under certain conditions, prepare versions to help meet demand, and GLP-1 medicines have seen periods of very high demand. A product's FDA shortage status can change over time, which is one reason access to compounded versions is handled case by case and framed as a clinical decision rather than a simple purchase.

Crucially, an independent licensed physician may prescribe a compounded medication when clinically appropriate. But no responsible source should ever blur the line by suggesting a compounded version is FDA-approved, or by claiming one product is superior to another beyond what FDA labeling supports. Both framings are inaccurate.

How a clinician chooses

The most important point in this whole comparison is that the choice is not yours to make from a webpage, and it is not ours to make in an article. The appropriate option is decided by an independent licensed clinician after evaluating your health history, current medications, and goals. Starting an evaluation does not guarantee any prescription, and a good clinician will decline treatment when it is not appropriate.

A clinician weighs many individual factors: your medical history, other conditions and medications, and what is available and suitable at the time. Because a product's FDA shortage status and other circumstances can change, the reasoning behind choosing a brand or a compounded option is genuinely case by case. The role of the evaluation is precisely to let a licensed professional apply that judgment to you as an individual.

This is also why who you go through matters. A legitimate service is built around a real clinical relationship, evaluation, prescription only where appropriate, dispensing through a licensed pharmacy, and follow-up, rather than a checkout that sells a specific medication to anyone who asks. You can read more about our standards on the About the Journal page and browse related explainers in Weight Management.

How to spot an unsafe source

Because compounded medications rely on the standards of the pharmacy and prescriber rather than FDA product review, recognizing an unsafe source is genuinely protective. Warning signs worth taking seriously include:

• No evaluation and no clinician. Any site willing to sell semaglutide without a real clinical review is a serious red flag.
• Opaque sourcing. A legitimate service can tell you it works with licensed U.S. pharmacies; be wary of unverified or overseas sources.
• Blurring the regulatory line. Any suggestion that compounded semaglutide is FDA-approved, or that one option is simply "better," is inaccurate and a reason for caution.
• Dramatic promises and urgency. Guaranteed outcomes, specific results, countdown timers, and hard-sell tactics have no place in a clinical decision.

The reassuring flip side is that a trustworthy service tends to look boringly clinical: an evaluation, an independent licensed prescriber, a named licensed pharmacy, and follow-up. If obtaining a prescription medicine feels frictionless and salesy, treat that as information.

What the two do share

It would be misleading to present these as entirely different medicines. Both involve semaglutide, the same GLP-1 receptor agonist acting on the same appetite and blood-sugar pathways, and both are intended to support, not replace, a reduced-calorie diet and increased physical activity. Both should be used only under a clinician's direction, typically started at a low dose and adjusted gradually, with follow-up along the way.

The commonalities are exactly why the regulatory distinction deserves emphasis rather than the reverse. Sharing an active molecule does not make an FDA-approved product and a compounded preparation equivalent in oversight, and honest patient education keeps both truths in view: the same active ingredient, but a different regulatory status and a different chain of quality assurance. For a deeper look at the medication itself, see our explainer on compounded semaglutide.

How either option is prescribed and monitored

Whichever option a clinician decides on, the responsible path looks broadly the same, and it begins with a clinician rather than a shopping cart. In general terms, the process tends to follow these steps:

1. An online evaluation covering your health history, current medications, allergies, and goals.
2. Clinician review, in which an independent licensed medical professional decides whether treatment is appropriate, and declines when it is not. Starting an evaluation does not guarantee a prescription.
3. Dispensing through a licensed pharmacy, which for a compounded medication means a licensed compounding pharmacy operating under recognized standards.
4. Follow-up, with treatment typically started at a low dose and adjusted gradually under clinical guidance.

Monitoring is not an afterthought in either case. Because semaglutide is prescribed in the context of your broader health and any other conditions or medications, ongoing follow-up lets a clinician review how you are tolerating treatment and adjust as needed. This is true whether the prescription is for an FDA-approved product or a compounded preparation, the clinical relationship, not the label alone, is what keeps treatment appropriate over time.

Questions worth asking your clinician

Because the brand-versus-compounded distinction can be confusing, going into an evaluation with a few questions ready helps you make an informed decision. You might consider asking:

• Given my health history, is a GLP-1 medication appropriate for me at all?
• If a compounded medication is recommended, which licensed pharmacy prepares it, and what does its "not FDA-approved" status mean in practice?
• What side effects should I expect, and which ones mean I should contact you right away?
• How will my dose be started and adjusted, and how often will we check in?
• How should I store and handle the medication, and what do I do about a missed dose?

Questions like these keep you an active participant rather than a passive purchaser. They also help you tell a trustworthy service apart from an unsafe one: a legitimate provider will answer plainly, will not blur the regulatory line, and will frame the decision as a clinical one made for you as an individual.

The bottom line

Wegovy® and compounded semaglutide share the same active molecule but differ where it counts: Wegovy® (semaglutide) is FDA-approved with FDA-reviewed labeling, while compounded semaglutide is prepared by a licensed pharmacy for an individual patient and is not FDA-approved or reviewed by the FDA for safety, efficacy, or quality. Neither is inherently "better" as a blanket statement, the appropriate option is an individual clinical decision. The only way to know what is right for you is an evaluation with an independent licensed clinician who can weigh your health, history, and goals.

Frequently asked questions